Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial

BACKGROUND: There is high medical need for safe long-term immunosuppression monotherapy in kidney transplantation. Selective targeting of post-transplant alloantigen-(re)activated effector-T cells by anti-TNF antibodies after global T cell depletion may allow safe drug minimization, however, it is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Viklicky, Ondrej, Hruba, Petra, Tomiuk, Stefan, Schmitz, Sabrina, Gerstmayer, Bernhard, Sawitzki, Birgit, Miqueu, Patrick, Mrazova, Petra, Tycova, Irena, Svobodova, Eva, Honsova, Eva, Janssen, Uwe, Volk, Hans-Dieter, Reinke, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234822/
https://www.ncbi.nlm.nih.gov/pubmed/28085915
http://dx.doi.org/10.1371/journal.pone.0169624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234822/
https://www.ncbi.nlm.nih.gov/pubmed/28085915
http://dx.doi.org/10.1371/journal.pone.0169624

Ejemplares similares